■这项研究深入研究了那不勒斯3南部当地卫生机构的两年阿片类药物处方趋势,坎帕尼亚地区,意大利。这项研究旨在阐明处方模式,人口统计,以及占全国总数1.7%的人口中的剂量类别。讨论了人工智能研究的前景。
■从原始数据集,从2022年1月到2023年10月,我们处理了多个变量,包括人口统计数据,药物,剂量,药物消费,和管理路线。根据规定的每日剂量(DDD)计算分配量。
■分析揭示了阿片类药物治疗的保守方法。在20岁以下的受试者中,处方在2022年占2.1%,在2023年下降到1.4%。扑热息痛/可待因的药物组合是最常用的处方,其次是他汀类药物。大约三分之二的消费涉及口服制剂。透皮制剂为15%(芬太尼9.8%,2022年丁丙诺啡5.1%);16.6%(芬太尼10%,丁丙诺啡6.6%),2023年。这些数据通过DDD分析得到证实。趋势分析表明,从2022年到2023年,成年人(40-69岁)的处方阿片类药物数量显着减少(p<0.001)。速效阿片类药物(ROO)的研究,专门用于突破性癌症疼痛的药物,在女性中显示出更高的剂量(>267微克)消费量,而男性的剂量较低(<133mcg)。芬太尼果胶喷鼻剂约占所有ROO的五分之一。
■尽管有限制,该研究为涉及重要研究人群的处方实践提供了有价值的见解。调查结果强调了需要量身定制的处方方法,认识到疼痛管理在不同情况下的复杂性。这项研究可以为正在进行的关于阿片类药物使用的讨论做出贡献,倡导创新策略,优化治疗结果,同时降低潜在风险。
UNASSIGNED: This study delves into the two-year opioid prescription trends in the Local Sanitary Agency Naples 3 South, Campania Region, Italy. The research aims to elucidate prescribing patterns, demographics, and dosage categories within a population representing 1.7% of the national total. Perspectives on artificial intelligence research are discussed.
UNASSIGNED: From the original dataset, spanning from January 2022 to October 2023, we processed multiple variables including demographic data, medications, dosages, drug consumption, and administration routes. The dispensing quantity was calculated as defined daily doses (DDD).
UNASSIGNED: The analysis reveals a conservative approach to opioid therapy. In subjects under the age of 20, prescriptions accounted for 2.1% in 2022 and declined to 1.4% in 2023. The drug combination paracetamol/codeine was the most frequently prescribed, followed by
tapentadol. Approximately two-thirds of the consumption pertains to oral formulations. Transdermal formulations were 15% (fentanyl 9.8%, buprenorphine 5.1%) in 2022; and 16.6% (fentanyl 10%, buprenorphine 6.6%) in 2023. These data were confirmed by the DDD analysis. The trend analysis demonstrated a significant reduction ( p < 0.001) in the number of prescribed opioids from 2022 to 2023 in adults (40-69 years). The study of rapid-onset opioids (ROOs), drugs specifically used for breakthrough cancer pain, showed higher dosage (>267 mcg) consumption among women, whereas a lower dosage (<133 mcg) was calculated for men. Fentanyl pectin nasal spray accounted for approximately one-fifth of all ROOs.
UNASSIGNED: Despite limitations, the study provides valuable insights into prescribing practices involving an important study population. The findings underscore the need for tailored approaches to prescribing practices, recognizing the complexities of pain management in different contexts. This research can contribute to the ongoing discourse on opioid use, advocating for innovative strategies that optimize therapeutic outcomes while mitigating potential risks.